Table 1.

Disease diagnosis, patient characteristics, growth characteristics, and viral status of the TLBR-1, -2, and -3 cell lines

Patient 1: TLBR-1Patient 2: TLBR-2Patient 3: TLBR-3
Patient diagnosisALK seroma–associated T-ALCL, absent t(2;5) 42-y-old femaleALK seroma–associated T-ALCL, absent t(2;5) 43-y-old femaleALK seroma–associated T-ALCL, absent t(2;5) 45-y-old female
Implant typeTextured saline Nagor SFX-HP 250ccTextured saline McGhan/Inamed/Allergan 410ccTextured saline McGhan/Inamed/Allergan 480cc
Clinical presentationUnilateral malignant seroma, recurrent after initial drainageUnilateral malignant seroma, recurrent after initial drainageUnilateral malignant seroma, recurrent after initial drainage, and mass lesions attached to the capsule seen by imaging
Tumor specimen cytologyLarge mononuclear CD30+ ALKCD4+ CD8+ TIA-1+ Perforin+ Keratin PAX5 CD20 anaplastic lymphoma cellsLarge mononuclear CD30+ ALK CD45+ CD20 CD15 CD43Cytokeratins (Cam 5.2) anaplastic lymphoma cellsLarge mononuclear CD30+ ALK CD45+ CD4+ CD43+ TIA-1+ CD8 CD15 CD20 CD68 PAX5 anaplastic lymphoma cells
Patient treatment and outcomeSurgery (bilateral implant removal and capsulectomy) and radiation therapy (40 Gy delivered in 20 fractions)Surgery (bilateral implant removal and capsulectomy)Surgery (bilateral implant removal and capsulectomy) and radiation therapy (36 Gy delivered in 20 fractions)
Patient in remission at time of publication (3 y after initial presentation)Recurrent disease involving axillary lymph nodes, supraclavicular fossa, mediastinum, and bilateral lung infiltratesPatient in remission at time of publication (14 mo after initial presentation)
Chemotherapy and radiation therapy, unsuccessful
Patient died of disease 9 mo after initial presentation
Cell line cultureSuspension culture, IL-2–dependentSuspension culture, IL-2–dependentSuspension culture, IL-2–dependent
Doubling time55 h37 h77 h
Viral statusEBV, HTLV1/2, HPVEBV, HTLV1/2, HPVEBV, HTLV1/2, HPV
Malignant originKaryotype, TCRγ rearrangement, heterotransplantationKaryotype, TCRγ rearrangementKaryotype, TCRγ rearrangement
Year established200920112011